Efflux Pump Mediated Second-Line Tuberculosis Drug ResistanceLesibana Anthony Malinga1,2*, Anton Stoltz2 and Martie van der Walt1
- *Corresponding Author:
- Lesibana Anthony Malinga
Medical Research Council, TB Platform, Pretoria, South Africa
E-mail: [email protected]
Received date: Jul 01, 2016; Accepted date: Aug 22, 2016; Published date: Aug 31, 2016
Citation: Malinga LA, Stoltz A, Van der Walt M (2016) Efflux Pump Mediated Second-Line Tuberculosis Drug Resistance. Mycobact Dis 6:222. doi:10.4172/2161-1068.1000222
Copyright: © 2016 Malinga LA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The burden and spread of drug-resistant tuberculosis disease is a major public health problem worldwide. The causative agent, Mycobacterium tuberculosis uses several mechanisms to counteract therapy through drugresistance. A major and most common mechanism of drug-resistance is mediated through target mutations. Efflux pumps are emerging as potential agents of drug-resistance and treatment failure. In this review we explore the origin and principles of efflux pump-mediated resistance and determine their impact on second-line drugs used against extensively drug resistant tuberculosis. Inhibition of efflux pumps as a therapeutic intervention is also discussed.